Advances in the Application of Single-Cell Sequencing Technology in the Treatment and Prognostic Assessment of Acute Myeloid Leukemia
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i1.3678
Abstract
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy. Traditional treatment methods have proven inadequate, resulting in poor treatment outcomes. The rapid advancement of single-cell sequencing technology in recent years has provided a new perspective for AML research. This review summarizes the progress in the application of single-cell sequencing technology in the treatment and prognostic assessment of AML. In terms of treatment, this technology can uncover the heterogeneity of AML cells, provide a basis for personalized treatment strategies, monitor cellular responses, and assess treatment efficacy. In terms of prognostic assessment, single-cell sequencing technology can identify prognostic markers, construct prognostic models, and evaluate the impact of the immune microenvironment on prognosis. Despite challenges such as high costs and complex data interpretation, the integration of multi-omics analysis is expected to become a future trend, potentially enhancing AML treatment outcomes and patient survival rates through continuous technological innovation and optimization.
Keywords
acute myeloid leukemia, single-cell sequencing, treatment, prognostic assessment
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1]Kantarjian, H.M., et al., Acute myeloid leukemia management and research in 2025. CA Cancer J Clin, 2025. 75(1): p. 46-67.
[2]Shimony, S., M. Stahl, and R.M. Stone, Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol, 2023. 98(3): p. 502-526.
[3]van Galen, P., et al., Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell, 2019. 176(6): p. 1265-1281.e24.
[4]Wu, J., et al., A single-cell survey of cellular hierarchy in acute myeloid leukemia. J Hematol Oncol, 2020. 13(1): p. 128.
[5]Fang, D.D., et al., MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discov, 2021. 7(1): p. 90.
[6]Petti, A.A., et al., A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing. Nat Commun, 2019. 10(1): p. 3660.
[7]Karantanos, T. and R.J. Jones, Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance. Adv Exp Med Biol, 2019. 1139: p. 153-169.
[8]Peroni, E., et al., Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment. J Exp Clin Cancer Res, 2023. 42(1): p. 259.
[9]Robinson, T.M., et al., Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Sci Adv, 2023. 9(38): p. eadg0488.
[10]Wang, J., et al., A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia. Signal Transduct Target Ther, 2024. 9(1): p. 358.
[11]Zhai, X. and X. Jiang, Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias. Biomedicines, 2022. 10(8).
[12]Zhou, J. and W.J. Chng, Unveiling novel insights in acute myeloid leukemia through single-cell RNA sequencing. Front Oncol, 2024. 14: p. 1365330.
[13]Liu, J., et al., Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance. Exp Hematol Oncol, 2024. 13(1): p. 12.
[14]Levis, M. and A.E. Perl, Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv, 2020. 4(6): p. 1178-1191.
[15]McMahon, C.M., et al., Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov, 2019. 9(8): p. 1050-1063.
[16]Tecik, M. and A. Adan, Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches. Onco Targets Ther, 2022. 15: p. 1449-1478.
[17]Zou, Y.X., H.Y. Zhang, and H.B. Hu, Big data and single-cell sequencing in acute myeloid leukemia research. Medcomm-Oncology, 2023. 2(3).
[18]Chen, S.L., et al., The Role of the HOXA Gene Family in Acute Myeloid Leukemia. Genes (Basel), 2019. 10(8).
[19]Miao, P., et al., Establishment and verification of a TME prognosis scoring model based on the acute myeloid leukemia single-cell transcriptome. Sci Rep, 2024. 14(1): p. 19811.
[20]Xiong, Q., et al., Single‑cell RNA sequencing of t(8;21) acute myeloid leukemia for risk prediction. Oncol Rep, 2020. 43(4): p. 1278-1288.
[21]Guo, R., et al., Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark Res, 2021. 9(1): p. 15.
[22]Daver, N., et al., T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia, 2021. 35(7): p. 1843-1863.
[23]Marofi, F., et al., Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Research & Therapy, 2021. 12(1).
[2]Shimony, S., M. Stahl, and R.M. Stone, Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol, 2023. 98(3): p. 502-526.
[3]van Galen, P., et al., Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell, 2019. 176(6): p. 1265-1281.e24.
[4]Wu, J., et al., A single-cell survey of cellular hierarchy in acute myeloid leukemia. J Hematol Oncol, 2020. 13(1): p. 128.
[5]Fang, D.D., et al., MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discov, 2021. 7(1): p. 90.
[6]Petti, A.A., et al., A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing. Nat Commun, 2019. 10(1): p. 3660.
[7]Karantanos, T. and R.J. Jones, Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance. Adv Exp Med Biol, 2019. 1139: p. 153-169.
[8]Peroni, E., et al., Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment. J Exp Clin Cancer Res, 2023. 42(1): p. 259.
[9]Robinson, T.M., et al., Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Sci Adv, 2023. 9(38): p. eadg0488.
[10]Wang, J., et al., A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia. Signal Transduct Target Ther, 2024. 9(1): p. 358.
[11]Zhai, X. and X. Jiang, Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias. Biomedicines, 2022. 10(8).
[12]Zhou, J. and W.J. Chng, Unveiling novel insights in acute myeloid leukemia through single-cell RNA sequencing. Front Oncol, 2024. 14: p. 1365330.
[13]Liu, J., et al., Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance. Exp Hematol Oncol, 2024. 13(1): p. 12.
[14]Levis, M. and A.E. Perl, Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv, 2020. 4(6): p. 1178-1191.
[15]McMahon, C.M., et al., Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov, 2019. 9(8): p. 1050-1063.
[16]Tecik, M. and A. Adan, Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches. Onco Targets Ther, 2022. 15: p. 1449-1478.
[17]Zou, Y.X., H.Y. Zhang, and H.B. Hu, Big data and single-cell sequencing in acute myeloid leukemia research. Medcomm-Oncology, 2023. 2(3).
[18]Chen, S.L., et al., The Role of the HOXA Gene Family in Acute Myeloid Leukemia. Genes (Basel), 2019. 10(8).
[19]Miao, P., et al., Establishment and verification of a TME prognosis scoring model based on the acute myeloid leukemia single-cell transcriptome. Sci Rep, 2024. 14(1): p. 19811.
[20]Xiong, Q., et al., Single‑cell RNA sequencing of t(8;21) acute myeloid leukemia for risk prediction. Oncol Rep, 2020. 43(4): p. 1278-1288.
[21]Guo, R., et al., Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark Res, 2021. 9(1): p. 15.
[22]Daver, N., et al., T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia, 2021. 35(7): p. 1843-1863.
[23]Marofi, F., et al., Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Research & Therapy, 2021. 12(1).
Copyright © 2025 Dandan Kang, Shenxian Qian
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
